Skip to main content
MJFF in the News

Press Releases

Browse current and past press releases from The Michael J. Fox Foundation.

From
To
  • Default content image

    The Michael J. Fox Foundation for Parkinson’s Research Adopts Open Access Publication Policy

    NEW YORK (March 2, 2020) — In keeping with its core values of transparency and scientific collaboration to accelerate the development of new treatments, The Michael J. Fox Foundation for Parkinson’s…

  • Default content image

    The Michael J. Fox Foundation for Parkinson’s Research Announces New Chairman of the Board, Biopharma Leader Skip Irving

    NEW YORK, February 27, 2020 — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced the appointment of Skip Irving as chairman of its Board of Directors. Irving’s 30-year track…

  • Default content image

    The Michael J. Fox Foundation Relaunches Parkinson’s Clinical Study Matching Tool, Fox Trial Finder, with Optimized Features and Accessibility

    The newly designed Fox Trial Finder connects volunteers to hundreds of actively recruiting Parkinson’s clinical studies   More than 91,000 participants — people with and without Parkinson’s disease …

  • Default content image

    The Michael J. Fox Foundation Launches 2020 Fox Trot 5K Run/Walk Series across the United States to Raise $1.2M for Parkinson’s Disease Research

    Runners and walkers of all ages, abilities and speeds are encouraged to participate View the entire list of events and register at foxtrot.org NEW YORK (February 24, 2020) – The Michael J. Fox…

  • Default content image

    The Michael J. Fox Foundation and Sage Bionetworks Launch $25,000 BEAT-PD DREAM Challenge

    NEW YORK (Jan. 13, 2020) – The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Sage Bionetworks have partnered with Evidation Health, Northwestern University, Radboud University Medical…

  • Default content image

    Though Safe and Tolerable, Nilotinib Does Not Show Promise for Benefit in Phase II Nilotinib for Parkinson’s Disease (NILO-PD) Trial

    Nilotinib seen to be safe and tolerable, but study strictly excluded those with heart issues or other health challenges No observed clinical benefit nor biological effect seen c-Abl remains target…

  • Default content image

    Accelerating Medicines Partnership Launches Data Knowledge Portal for Parkinson’s Disease

    NEW YORK (November 22, 2019) -- The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298…

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.